Abstract Neoadjuvant Targeted Molecular Therapy in the setting of localized and locally
advanced renal cell carcinoma has emerged as a strategy to render primary renal tumors
amenable to planned surgical resection in settings where radical resection or nephron-
sparing surgery was not thought to be safe or feasible. Presurgical tumor reduction has been
demonstrated in a number of studies including a recently published randomized double-
blind placebo-controlled study, and an expanding body of literature suggests benefit in …